In a retrospective assessment using data from a software that titrates insulin doses in 91 US hospitals, non-ICU patients hospitalized due to COVID-19 that had hyperglycemia > 250 mg/dL (13.9 mmol/L) in the 2–3 days after hospitalization had an adjusted estimated hazard ratio of 7.17 (CI 95%: 2.62–19.62) for mortality compared to patients with BG < 140 mg/dL (7.8 mmol/L) in a multivariate analysis [49]. The gene discussed is INS; the disease is COVID-19.